Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$2.04 - $4.17 $136,288 - $278,589
-66,808 Reduced 3.73%
1,722,586 $3.86 Million
Q1 2024

May 09, 2024

BUY
$1.43 - $3.25 $2.56 Million - $5.82 Million
1,789,394 New
1,789,394 $5.14 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $85.1M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.